13G Shows Versant Venture Capital III, L.P. 19.6% Stake In Skye Biosciences
Portfolio Pulse from Benzinga Newsdesk
Versant Venture Capital III, L.P. has acquired a 19.6% stake in Skye Biosciences, according to a 13G filing.
August 28, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Versant Venture Capital III, L.P. has acquired a significant stake in Skye Biosciences, which could influence the company's strategic decisions.
The acquisition of a 19.6% stake by Versant Venture Capital III, L.P. in Skye Biosciences is a significant event. This could potentially influence the company's strategic decisions and direction, which could impact the stock price in the short term. The news is highly relevant and important for SKYE investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100